Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Become a member
  1. OncologyPRO
  2. Meeting Resources
  3. ESMO Breast Cancer Congress 2023

Gilead Sciences - BREAKING THROUGH: Overcoming challenges in the treatment of patients with triple-negative and HR+/HER2-metastatic breast cancer

A new era of treatment for HR+/HER2- mBC: What do the clinical data tell us?

Date

12 May 2023

Session

Gilead Sciences - BREAKING THROUGH: Overcoming challenges in the treatment of patients with triple-negative and HR+/HER2-metastatic breast cancer

Presenters

Komal Jhaveri

Authors

K. Jhaveri

Author affiliations

  • Memorial Sloan Kettering Evelyn H. Lauder Breast Center, New York/US

Resources

This content is available to ESMO members and event participants.
Login

Resources from the same session

Closing remarks

Presenter: Wolfgang Janni

Session: Gilead Sciences - BREAKING THROUGH: Overcoming challenges in the treatment of patients with triple-negative and HR+/HER2-metastatic breast cancer

Resources:

Webcast

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings

  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.